5784 studies found for:    vaccine
Show Display Options
Rank Status Study
21 Completed
Has Results
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
Conditions: 13-valent Pneumococcal Vaccine;   Immunization;   Safety;   Antibody Response
Intervention: Biological: 13-valent pneumococcal conjugate vaccine
22 Completed
Has Results
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine;   Biological: Licensed comparator
23 Completed
Has Results
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
Condition: Influenza Disease
Interventions: Biological: Trivalent split influenza vaccine (TIV);   Biological: MF59-adjuvanted trivalent influenza vaccine (aTIV);   Biological: Licensed comparator trivalent split influenza vaccine (comparator TIV)
24 Recruiting Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: CYD Dengue and Japanese Encephalitis Vaccines;   Biological: Japanese Encephalitis and CYD Dengue Vaccines
25 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + OMV vaccine (rMenB +OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
26 Completed
Has Results
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal vaccine GSK1024850A;   Biological: Tritanrix-HepB/Hib;   Biological: measles;   Biological: Rotarix;   Biological: Local OPV
27 Completed
Has Results
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
28 Completed
Has Results
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Infections
Interventions: Biological: DTaP-HB-PRP~T vaccine + OPV;   Biological: Tritanrix-HepB/Hib™ + OPV vaccine;   Biological: Oral Polio Vaccine
29 Completed Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
Condition: Staphylococcal Infections
Interventions: Biological: SA4Ag vaccine low dose;   Procedure: Blood draw;   Procedure: Colonization swab sample;   Biological: SA4Ag vaccine mid dose;   Biological: SA4Ag vaccine high dose;   Biological: SA3Ag vaccine;   Procedure: Blood sample;   Biological: Placebo;   Procedure: Colonization swab samples
30 Unknown  An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
Conditions: Using Cocaine or Heroin in the Last 7 Days,;   Age Over 18 Years Old,;   Competent to Sign Informed Consent for HIV/HBV/HCV Testing,;   HIV/HBV Negatives Will be Randomized for HB Vaccine Study;   HIV Infections
Interventions: Biological: hepatitis B vaccine schedule;   Behavioral: HBV Vaccination Self-Efficacy Intervention
31 Completed
Has Results
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-IPV/Hib;   Biological: HBV;   Biological: PCV;   Biological: MMR
32 Active, not recruiting Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus;   Biological: DTaP IPV//Hib vaccine;   Biological: Placebo;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal vaccine
33 Active, not recruiting Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: AIDSVAX B/E;   Biological: Placebo for ALVAC-HIV;   Biological: Placebo for AIDSVAX B/E;   Biological: Hepatitis B vaccine;   Biological: Tetanus toxoid vaccine;   Biological: Placebo for hepatitis B vaccine;   Biological: Placebo for tetanus vaccine
34 Completed
Has Results
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
Condition: Streptococcal Infections
Interventions: Biological: Group B Streptococcus Trivalent Vaccine - 20/20/20 μg;   Other: Saline solution;   Biological: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg;   Biological: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg;   Biological: Group B Streptococcus Trivalent Vaccine - 5/5/5 μg;   Other: saline solution
35 Active, not recruiting Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Condition: Influenza
Interventions: Biological: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® Intradermal Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® High Dose Influenza Virus Vaccine (2013-2014 formulation)
36 Enrolling by invitation The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine
Condition: Rotavirus
Interventions: Biological: rotavirus vaccine;   Biological: measles-rubella vaccine;   Biological: measles-mumps-rubella vaccine
37 Completed
Has Results
Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects
Conditions: Influenza;   Myxovirus Infection
Intervention: Biological: Split, Inactivated, Trivalent Influenza Vaccine
38 Completed Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines
Condition: Influenza Disease
Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine;   Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine;   Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
39 Completed Swine Flu (Novel Influenza A H1N1) Vaccine Study
Condition: Influenza
Interventions: Biological: Baxter Novel Influenza A H1N1 Whole Virus Vaccine;   Biological: GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
40 Completed
Has Results
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Condition: Pandemic Influenza Disease
Interventions: Biological: Placebo;   Biological: Trivalent influenza virus vaccine (TIV);   Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1);   Biological: Adjuvanted trivalent influenza vaccine (aTIV)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years